...
首页> 外文期刊>Frontiers in Microbiology >In vivo Acquisition of Carbapenemase Gene bla KPC-2 in Multiple Species of Enterobacteriaceae through Horizontal Transfer of Insertion Sequence or Plasmid
【24h】

In vivo Acquisition of Carbapenemase Gene bla KPC-2 in Multiple Species of Enterobacteriaceae through Horizontal Transfer of Insertion Sequence or Plasmid

机译:通过插入序列的水平转移或质粒

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objectives: Current worldwide spread of carbapenem resistance in Enterobacteriaceae constitutes a critical public health threat. This study aims to investigate how carbapenem resistance is acquired in Enterobacteriaceae in patients during antimicrobial therapy. Methods: Clinical strains from the same anatomical site of the same patients that converted from carbapenem-susceptible to resistant during antimicrobial therapy and showed identical or similar PFGE patterns were identified. The similarly sized plasmids carried by the susceptible and resistant strains, the latter containing the carbapenemase genes, were sequenced and analyzed. Results: Paired strains were identified from four patients: three had neurosurgical conditions while the other had acute exacerbation of COPD. Two pairs of Klebsiella pneumoniae (KP1-S/R and KP2-S/R, S and R indicating susceptible and resistant strains, respectively), one pair of Morganella morganii (MM-S/R) and one pair of Enterobacter aerogenes (EA-S/R) were collected. All four carbapenem-resistant strains carried plasmids harboring bla _(KPC?2). Compared with the similarly sized plasmids in KP1-S and KP2-S, an insertion sequence that includes IS Kpn6 -like, bla _(KPC?2)and IS Kpn8 was noted in pKP1-R and pKP2-R. Strains MM-R and EA-R had bla _(KPC?2)-carrying plasmids not resembling plasmids in strains MM-S and EA-S suggesting their new acquisition while on therapy. Conclusions: Enterobacteriaceae can acquire carbapenem resistance during antimicrobial therapy through horizontal transfer of an insertion sequence or plasmid.
机译:目标:目前,碳青霉烯耐药性在肠杆菌科中的全球传播构成了严重的公共卫生威胁。这项研究旨在调查在抗菌治疗过程中肠杆菌科患者如何获得碳青霉烯抗药性。方法:鉴定来自同一患者同一解剖部位的临床菌株,该菌株在抗菌治疗期间从对碳青霉烯易感的转化为耐药,并显示出相同或相似的PFGE模式。对易感和抗性菌株携带的相似大小的质粒进行测序和分析,后者含有碳青霉烯酶基因。结果:从四名患者中鉴定出了配对菌株:三名患有神经外科疾病,另一名患有COPD急性加重。两对肺炎克雷伯菌(KP1-S / R和KP2-S / R,S和R分别指示易感和耐药菌株),一对摩根氏摩根氏菌(MM-S / R)和一对产气肠杆菌(EA) -S / R)。所有四种对碳青霉烯类耐药的菌株均携带带有bla_(KPCβ2)的质粒。与KP1-S和KP2-S中大小相似的质粒相比,在pKP1-R和pKP2-R中发现了包括IS Kpn6样,bla _(KPCβ2)和IS Kpn8的插入序列。菌株MM-R和EA-R带有bla_(KPC?2)携带质粒,与MM-S和EA-S菌株中的质粒不同,这表明它们在治疗时获得了新的捕获物。结论:肠杆菌科细菌通过水平转移插入序列或质粒可在抗菌治疗中获得碳青霉烯抗药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号